This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Global Life Sciences Trends And Opportunities 2012-2015

NEW YORK, April 2, 2013 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

Global Life Sciences Trends and Opportunities 2012-2015

Frost & Sullivan's global life sciences team analyzes the impact of important changes and key trends across the total pharmaceutical/biotechnology, diagnostics, and life sciences research industries. This research deliverable captures the global life sciences trends and opportunities for the period of 2012-2015, as supported by Frost & Sullivan's proprietary research and leading industry experts. Our global life sciences team is uniquely positioned to provide comprehensive analysis and guidance in the converging landscape. Topics include generics and biosimilars, emerging markets, pharmaceutical outsourcing, novel therapeutics, next generation diagnostics, research and development laboratories, and clinical laboratories.


Executive Summary 6Daunting Challenges for the Pharmaceutical Industry 12Pharma's New Growth Strategies 17Curbing the Costs of Drug Development 32Lean Laboratories—Doing More With Less 37Novel Biomarker Discovery Leading to Novel Therapeutics 41Genetic Technologies are Integral to Healthcare 47Conclusions 52Appendix 55The Frost & Sullivan Story 65

List of ExhibitsLife Sciences Trends and Opportunities: Executive Summary, Global, 2012-2015 7Life Sciences Trends and Opportunities: Growth Areas Now and Developing, Global, 2012-2015 8Life Sciences Trends and Opportunities: Companies to Watch, Global, 2012-2015 9Life Sciences Trends and Opportunities: Competitive Companies Tracked by Frost & Sullivan, Global, 2012 10Life Sciences Trends and Opportunities: Future Outlook for Healthcare Compared to Present, Global, 2012-2015 11Life Sciences Trends and Opportunities: Key Mergers and Acquisitions by Pharmaceutical Companies, Global, 2010-2012 14Life Sciences Trends and Opportunities: Open Innovation—Pfizer and Novartis, Global, 2011 24Life Sciences Trends and Opportunities: Open Innovation—GlaxoSmithKline and Eli Lilly, Global, 2011 25Life Sciences Trends and Opportunities: Healthcare Expenditure, Global, 2010-2020 26Life Sciences Trends and Opportunities: Co-development Models, U.S., 2012 36Non-Invasive Prenatal Testing Market: Level of Agreement that NIPT Should Replace Maternal Serum Screen, U.S., 2012 51Life Sciences Trends and Opportunities: Patent Expirations for Major Drugs, U.S., 2011-2016 56Life Sciences Trends and Opportunities: Patent Expirations for Top Biologics, U.S., 2011-2019 57Life Sciences Trends and Opportunities: Top M&A Deals, U.S., 2011-2016 59

To order this report: Global Life Sciences Trends and Opportunities 2012-2015

__________________________Contact Clare: US:(339) 368 6001 Intl:+1 339 368 6001

SOURCE Reportlinker

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $92.90 -0.77%
FB $117.65 -0.35%
GOOG $700.84 0.74%
TSLA $213.58 -4.00%
YHOO $36.96 2.70%


Chart of I:DJI
DOW 17,626.85 -24.41 -0.14%
S&P 500 2,051.41 +0.29 0.01%
NASDAQ 4,725.6260 -0.0130 -0.00%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs